Search

Omburtamab

[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. … [A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).

Matuzumab

Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

Peptide YY (3-36)

It reduces appetite and increases satiety in obese patients.

4-Hydroxytestosterone

[A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in … It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.

Butaperazine

Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].

Iproclozide

fatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

FP0011

FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

Tubocurarine

[A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen. … [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048]

Famphur